Nora Feeney

2.3k total citations · 2 hit papers
11 papers, 1.5k citations indexed

About

Nora Feeney is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Nora Feeney has authored 11 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Nora Feeney's work include Cancer Genomics and Diagnostics (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (3 papers). Nora Feeney is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (3 papers). Nora Feeney collaborates with scholars based in United States. Nora Feeney's co-authors include Cloud P. Paweletz, Geoffrey R. Oxnard, Pasi A. Jänne, Suzanne E. Dahlberg, Yuebi Hu, Allison O’Connell, Ryan S. Alden, Adrian G. Sacher, Stacy L. Mach and Daniel B. Costa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Nora Feeney

11 papers receiving 1.5k citations

Hit Papers

Assessment of Resistance Mechanisms and Clinical Implicat... 2016 2026 2019 2022 2018 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
    2018 513 citations Geoffrey R. Oxnard, Yuebi Hu et al. JAMA Oncology profile →
  2. Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
    2016 432 citations Adrian G. Sacher, Cloud P. Paweletz et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nora Feeney United States 8 1.1k 959 772 516 245 11 1.5k
Ryan S. Alden United States 10 1.2k 1.1× 1.0k 1.1× 719 0.9× 457 0.9× 264 1.1× 14 1.5k
Yuebi Hu United States 7 739 0.7× 533 0.6× 521 0.7× 369 0.7× 158 0.6× 10 1.0k
Allison O’Connell United States 6 933 0.8× 1.1k 1.1× 659 0.9× 448 0.9× 218 0.9× 9 1.4k
Aleksandra Markovets United States 16 1.1k 1.0× 392 0.4× 834 1.1× 573 1.1× 127 0.5× 39 1.4k
Nicholas A. Jessop United States 6 959 0.8× 289 0.3× 843 1.1× 676 1.3× 211 0.9× 9 1.3k
Georgiana Kuhlmann United States 5 920 0.8× 357 0.4× 753 1.0× 500 1.0× 109 0.4× 6 1.3k
Margaret C. Skokan United States 13 1.2k 1.1× 408 0.4× 928 1.2× 607 1.2× 204 0.8× 21 1.7k
Alexander F. Lovejoy United States 10 466 0.4× 983 1.0× 405 0.5× 915 1.8× 253 1.0× 24 1.5k
Rose McCormack United Kingdom 11 1.7k 1.5× 1.1k 1.2× 1.1k 1.4× 444 0.9× 207 0.8× 11 2.0k
Jianchun Duan China 23 1.1k 0.9× 673 0.7× 1.0k 1.3× 511 1.0× 139 0.6× 96 1.7k

Countries citing papers authored by Nora Feeney

Since Specialization
Citations

This map shows the geographic impact of Nora Feeney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nora Feeney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nora Feeney more than expected).

Fields of papers citing papers by Nora Feeney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nora Feeney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nora Feeney. The network helps show where Nora Feeney may publish in the future.

Co-authorship network of co-authors of Nora Feeney

This figure shows the co-authorship network connecting the top 25 collaborators of Nora Feeney. A scholar is included among the top collaborators of Nora Feeney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nora Feeney. Nora Feeney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Hu, Yuebi, Bryan C. Ulrich, Julianna Supplee, et al.. (2018). False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clinical Cancer Research. 24(18). 4437–4443. 290 indexed citations
2.
Kuang, Yanan, Allison O’Connell, Adrian G. Sacher, et al.. (2018). Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. Methods in molecular biology. 1768. 193–207. 5 indexed citations
3.
Guibert, Nicolas, Yuebi Hu, Nora Feeney, et al.. (2018). Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Annals of Oncology. 29(4). 1049–1055. 89 indexed citations
4.
Oxnard, Geoffrey R., Yuebi Hu, Kathryn F. Mileham, et al.. (2018). Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology. 4(11). 1527–1527. 513 indexed citations breakdown →
5.
Hu, Yuebi, Ryan S. Alden, Justin I. Odegaard, et al.. (2017). Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clinical Cancer Research. 23(23). 7351–7359. 63 indexed citations
6.
Oxnard, Geoffrey R., Yuebi Hu, Kathryn F. Mileham, et al.. (2017). OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms. Journal of Thoracic Oncology. 12(11). S1767–S1768. 13 indexed citations
7.
Oxnard, Geoffrey R., Yuebi Hu, Philip Tracy, et al.. (2017). Abstract 4112: Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC. Cancer Research. 77(13_Supplement). 4112–4112. 3 indexed citations
8.
Guibert, Nicolas, Cloud P. Paweletz, Yuebi Hu, et al.. (2017). Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.. Journal of Clinical Oncology. 35(15_suppl). 11529–11529. 8 indexed citations
9.
Yanagita, Masahiko, Amanda J. Redig, Cloud P. Paweletz, et al.. (2016). A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clinical Cancer Research. 22(24). 6010–6020. 92 indexed citations
10.
11.
Sacher, Adrian G., Cloud P. Paweletz, Suzanne E. Dahlberg, et al.. (2016). Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer. JAMA Oncology. 2(8). 1014–1014. 432 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryan S. Alden Breakdown of academic impact, for papers by Yuebi Hu Breakdown of academic impact, for papers by Allison O’Connell Breakdown of academic impact, for papers by Aleksandra Markovets Breakdown of academic impact, for papers by Nicholas A. Jessop Breakdown of academic impact, for papers by Georgiana Kuhlmann Breakdown of academic impact, for papers by Margaret C. Skokan Breakdown of academic impact, for papers by Alexander F. Lovejoy Breakdown of academic impact, for papers by Rose McCormack Breakdown of academic impact, for papers by Jianchun Duan
Rankless by CCL
2026